Phagenesis appoints chairman and ceo

Will lead the development of treatments for stroke victims

Phagenesis, a UK leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as chairman and Daniel Green as chief executive. They will lead the University of Manchester spin out in the development of a new class of treatments for stroke victims suffering from dysphagia, a condition that prevents or impairs the safe swallowing of food and drink.

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.

Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.

You may also like

Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Manufacturing

Kindeva to showcase complex drug delivery expertise at CPHI 2025

Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
Research & Development

AI-powered Viro3D becomes world’s largest database of human and animal virus proteins

Scientists at the MRC-University of Glasgow Centre for Virus Research have launched a free database containing structural models for 85,000 proteins from 4400 viruses, paving the way for faster development of vaccines and antiviral drugs
Subscribe now